Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.

PubWeight™: 4.74‹?› | Rank: Top 1%

🔗 View Article (PMID 12588269)

Published in JAMA on February 19, 2003


A Michael Lincoff1, John A Bittl, Robert A Harrington, Frederick Feit, Neal S Kleiman, J Daniel Jackman, Ian J Sarembock, David J Cohen, Douglas Spriggs, Ramin Ebrahimi, Gadi Keren, Jeffrey Carr, Eric A Cohen, Amadeo Betriu, Walter Desmet, Dean J Kereiakes, Wolfgang Rutsch, Robert G Wilcox, Pim J de Feyter, Alec Vahanian, Eric J Topol, REPLACE-2 Investigators

Author Affiliations

1: Department of Cardiovascular Medicine, Desk F25, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA.

Associated clinical trials:

Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3) | NCT00262054

Novel Approaches in Preventing and Limiting Events III Trial (NAPLES III): Bivalirudin in High-risk Bleeding Patients (NAPLESIII) | NCT01465503

Safety and Efficacy of Delayed Continuous Use of Bivalirudin 4 Hours After ePCI (COBER Study) | NCT04120961

Articles citing this

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA (2009) 6.80

Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation (2009) 2.93

Automated surveillance to detect postprocedure safety signals of approved cardiovascular devices. JAMA (2010) 1.83

Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial. Eur Heart J (2014) 1.59

Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention. JACC Cardiovasc Interv (2011) 1.57

Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ (2012) 1.51

The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int (2006) 1.47

The use of vascular closure devices and impact on major bleeding and net adverse clinical events (NACEs) in balloon aortic valvuloplasty: a sub-analysis of the BRAVO study. Catheter Cardiovasc Interv (2013) 1.40

Temporal trends in and factors associated with bleeding complications among patients undergoing percutaneous coronary intervention: a report from the National Cardiovascular Data CathPCI Registry. J Am Coll Cardiol (2012) 1.17

Percutaneous coronary intervention: recommendations for good practice and training. Heart (2005) 1.14

Opposition: Unfractionated heparin should no longer be used in the catheterization laboratory. ASEAN Heart J (2015) 1.07

Direct thrombin inhibitors. Br J Clin Pharmacol (2011) 1.01

Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv (2011) 0.95

Hospital percutaneous coronary intervention appropriateness and in-hospital procedural outcomes: insights from the NCDR. Circ Cardiovasc Qual Outcomes (2012) 0.94

Temporal trends in gastrointestinal bleeding associated with percutaneous coronary intervention: analysis of the 1998-2006 Nationwide Inpatient Sample (NIS) database. Am Heart J (2011) 0.94

The frequency of vascular complications associated with the use of vascular closure devices varies by indication for cardiac catheterization. Clin Res Cardiol (2011) 0.92

The transfusion problem: role of aberrant S-nitrosylation. Transfusion (2011) 0.91

Red blood cell distribution width and long-term outcome in patients undergoing percutaneous coronary intervention in the drug-eluting stenting era: a two-year cohort study. PLoS One (2014) 0.90

The economic burden of complications during percutaneous coronary intervention. Qual Saf Health Care (2007) 0.90

Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. Eur Heart J (2009) 0.89

Comparison of bivalirudin and radial access across a spectrum of preprocedural risk of bleeding in percutaneous coronary intervention: analysis from the national cardiovascular data registry. Circ Cardiovasc Interv (2013) 0.88

Comparison of anti-thrombotic strategies using Bivalirudin, Heparin plus Glycoprotein IIb/IIIa inhibitors and Unfractionated Heparin Monotherapy for patients undergoing percutaneous coronary intervention - A single centre observational study. Indian Heart J (2015) 0.88

Clinical end point definitions after percutaneous coronary intervention and their relationship to late mortality: an assessment by attributable risk. Heart (2005) 0.86

New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin. Br J Pharmacol (2005) 0.86

Safety and efficacy of bivalirudin with glycoprotein IIb/IIIa for high-risk percutaneous coronary intervention. Indian Heart J (2012) 0.85

Prognostic significance of bleeding location and severity among patients with acute coronary syndromes. JACC Cardiovasc Interv (2013) 0.85

Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review. Eur Heart J (2013) 0.84

Should bivalirudin replace heparin during percutaneous coronary interventions? JAMA (2003) 0.83

Anti-platelet therapy: glycoprotein IIb-IIIa antagonists. Br J Clin Pharmacol (2011) 0.83

Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment. Clin Res Cardiol (2007) 0.83

Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction. Heart (2004) 0.82

Incidence and predictors of radial artery occlusion associated transradial catheterization. Int J Med Sci (2013) 0.82

Safety of immediate reversal of anticoagulation by protamine to reduce bleeding complications after infarct artery stenting for acute myocardial infarction and adjunctive abciximab therapy. J Thromb Thrombolysis (2010) 0.82

Antiplatelet therapy in patients undergoing percutaneous coronary intervention: economic considerations. Pharmacoeconomics (2013) 0.81

Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Drug Des Devel Ther (2010) 0.81

Clinical and economic studies of eptifibatide in coronary stenting. Ther Clin Risk Manag (2014) 0.81

Successful use of bivalirudin for superior vena cava recanalization and stent placement in a child with heparin-induced thrombocytopenia. Pediatr Cardiol (2008) 0.80

The AmBulatory Closure Device Percutaneous Intervention (ABCD-PCI) study: a single-center experience. Proc (Bayl Univ Med Cent) (2011) 0.80

Eptifibatide: The evidence for its role in the management of acute coronary syndromes. Core Evid (2010) 0.80

Actual Role of Platelet Glycoprotein IIb/IIIa Receptor Inhibitors as Adjunctive Pharmacological Therapy to Primary Angioplasty in Acute Myocardial Infarction: In the Light of Recent Randomized Trials and Observational Studies with Bivalirudin. Open Cardiovasc Med J (2010) 0.80

Critical Appraisal of Bivalirudin versus Heparin for Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials. PLoS One (2015) 0.80

Sensitivity of a modified ACT test to levels of bivalirudin used during cardiac surgery. J Extra Corpor Technol (2005) 0.80

Outcome of the HORIZONS-AMI trial: bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty. Vasc Health Risk Manag (2012) 0.80

Design and Rationale of the Femoral Closure versus Radial Compression Devices Related to Percutaneous Coronary Interventions (FERARI) Study. Clin Med Insights Cardiol (2015) 0.79

Population pharmacokinetics and pharmacodynamics of bivalirudin in young healthy Chinese volunteers. Acta Pharmacol Sin (2012) 0.79

Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin. Vasc Health Risk Manag (2008) 0.78

Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. Clin Res Cardiol (2013) 0.78

The effect of bivalirudin and closure device on bleeding outcomes after percutaneous coronary interventions. Open Heart (2014) 0.78

Validation of long-term benefits of bivalirudin versus unfractionated heparin in routine clinical practice after percutaneous coronary intervention. Am J Cardiol (2010) 0.78

Emerging therapies for acute coronary syndromes. Front Pharmacol (2011) 0.78

Implications of bleeding in acute coronary syndrome and percutaneous coronary intervention. Vasc Health Risk Manag (2011) 0.78

Identification of hospital outliers in bleeding complications after percutaneous coronary intervention. Circ Cardiovasc Qual Outcomes (2014) 0.77

Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS. Eur Heart J Acute Cardiovasc Care (2013) 0.77

The Role of Glycoprotein IIb/IIIa Inhibitors- A Promise Not Kept? Curr Cardiol Rev (2008) 0.77

Direct thrombin inhibitors in cardiovascular disease. Nat Rev Cardiol (2012) 0.77

Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention in Patients at High Risk for Bleeding. Int J Angiol (2014) 0.77

The REG1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome. Future Cardiol (2012) 0.77

Recent Advances in the Treatment of ST-Segment Elevation Myocardial Infarction. Scientifica (Cairo) (2012) 0.77

Comparison of new adenosine diphosphate receptor antagonists with clopidogrel in patients with coronary artery disease: a meta-analysis. Heart Vessels (2014) 0.77

Bivalirudin versus unfractionated heparin: a meta-analysis of patients receiving percutaneous coronary intervention for acute coronary syndromes. Open Heart (2015) 0.76

Bivalirudin in percutaneous coronary intervention. Vasc Health Risk Manag (2006) 0.76

Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention. Vasc Health Risk Manag (2010) 0.76

Emergency cardiac surgery in patients with acute coronary syndromes: a review of the evidence and perioperative implications of medical and mechanical therapeutics. Anesth Analg (2011) 0.76

The direct thrombin inhibitor argatroban: a review of its use in patients with and without HIT. Biologics (2007) 0.76

Promotion of proinflammatory interactions between platelets and monocytes by unfractionated heparin. Heart (2006) 0.76

Enoxaparin injection for the treatment of high-risk patients with non-ST elevation acute coronary syndrome. Vasc Health Risk Manag (2007) 0.76

Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trial. Clin Res Cardiol (2011) 0.76

The comparative efficacy of bivalirudin is markedly attenuated by use of radial access: insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium. Eur Heart J (2015) 0.75

Optimal oral antithrombotic regimes for patients with acute coronary syndrome: a network meta-analysis. PLoS One (2014) 0.75

Trends in use of anti-thrombotic agents and outcomes in patients with non-ST-segment elevation myocardial infarction (NSTEMI) managed with an invasive strategy. Indian Heart J (2016) 0.75

Adjunct bivalirudin dosing protocol for neuro-endovascular procedures. J Vasc Interv Neurol (2008) 0.75

Angiographic and clinical outcomes of bivalirudin versus heparin in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Can J Cardiol (2006) 0.75

Incorporating linked healthcare claims to improve confounding control in a study of in-hospital medication use. Drug Saf (2015) 0.75

Prolonged High-Dose Bivalirudin Infusion Reduces Major Bleeding Without Increasing Stent Thrombosis in Patients Undergoing Primary Percutaneous Coronary Intervention: Novel Insights From an Updated Meta-Analysis. J Am Heart Assoc (2016) 0.75

Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention. Vasc Health Risk Manag (2009) 0.75

Successful anticoagulation with fresh frozen plasma for cardiopulmonary bypass in a patient with heparin resistance: a cautionary tale. BMJ Case Rep (2013) 0.75

Predicting and evaluating the effect of bivalirudin in cardiac surgical patients. IEEE Trans Biomed Eng (2014) 0.75

Long-term follow-up results in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents: results from a single high-volume PCI centre. BMJ Open (2014) 0.75

A Predictive Model for the Anticoagulant Bivalirudin Administered to Cardiac Surgical Patients. Proc IEEE Conf Decis Control (2013) 0.75

Thrombin inhibitors and cardiopulmonary bypass. J Extra Corpor Technol (2006) 0.75

Heparin Versus Bivalirudin in Acute Myocardial Infarction: Unfractionated Heparin Monotherapy Elevated to Primary Treatment in Contemporary Percutaneous Coronary Intervention. Open Cardiovasc Med J (2016) 0.75

Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview. Vasc Health Risk Manag (2011) 0.75

Risk guided use of the direct thrombin inhibitor bivalirudin: insights from recent trials and analyses. J Thorac Dis (2016) 0.75

HEAT-PPCI: A clear and welcome win for heparin. Glob Cardiol Sci Pract (2014) 0.75

Changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention. Heart (2005) 0.75

The impact of vascular access for in-hospital major bleeding in patients with acute coronary syndrome at moderate- to very high-bleeding risk. J Korean Med Sci (2013) 0.75

Bivalirudin Anticoagulant Therapy With or Without Platelet Glycoprotein IIb/IIIa Inhibitors During Transcatheter Coronary Interventional Procedures: A Meta-Analysis. Medicine (Baltimore) (2015) 0.75

Trends in major entry site complications from percutaneous coronary intervention (from the Dynamic Registry). Am J Cardiol (2013) 0.75

Glycoprotein IIb-IIIa inhibitors - do we still need them? Indian Heart J (2013) 0.75

Risk of Bleeding in End-Stage Liver Disease Patients Undergoing Cardiac Catheterization. Tex Heart Inst J (2015) 0.75

Bivalirudin: the relevance in today's interventional practice. Indian Heart J (2012) 0.75

Impact of bivalirudin on mortality and bleeding complications in acute coronary syndrome patients undergoing invasive revascularization : A real world experience. Wien Klin Wochenschr (2016) 0.75

Glycoprotein IIb/IIIa inhibition in percutaneous coronary interventions. JAMA (2003) 0.75

Biomarkers and Bioassays for Cardiovascular Diseases: Present and Future. Biomark Insights (2008) 0.75

Efficacy and safety of bivalirudin versus heparin in patients with diabetes mellitus undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. Medicine (Baltimore) (2017) 0.75

Management of elderly patients with a non-ST-segment-elevation acute coronary syndrome. Neth Heart J (2017) 0.75

The anticoagulant effect of heparin during radiofrequency ablation (RFA) in patients taking apixaban or rivaroxaban. J Interv Card Electrophysiol (2017) 0.75

Articles by these authors

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet (2005) 21.91

2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25

Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03

Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med (2010) 17.57

Assessing the impact of population stratification on genetic association studies. Nat Genet (2004) 16.28

Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med (2003) 13.29

Human genetic variation and its contribution to complex traits. Nat Rev Genet (2009) 12.11

Universal definition of myocardial infarction. Circulation (2007) 11.69

Ethical and scientific implications of the globalization of clinical research. N Engl J Med (2009) 11.42

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 11.06

Strategies for multivessel revascularization in patients with diabetes. N Engl J Med (2012) 10.79

Guidelines on the management of valvular heart disease (version 2012). Eur Heart J (2012) 10.70

Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail (2012) 10.38

Clinical end points in coronary stent trials: a case for standardized definitions. Circulation (2007) 10.31

Evaluation of next generation sequencing platforms for population targeted sequencing studies. Genome Biol (2009) 9.59

Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med (2015) 9.58

2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43

Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med (2013) 8.91

Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59

Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J (2008) 8.20

Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA (2006) 7.81

Diagnostic accuracy of 64-slice computed tomography coronary angiography: a prospective, multicenter, multivendor study. J Am Coll Cardiol (2008) 7.56

Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet (2006) 7.33

Effect of direct-to-consumer genomewide profiling to assess disease risk. N Engl J Med (2011) 6.90

A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J (2003) 6.88

Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet (2003) 6.85

Common vs. rare allele hypotheses for complex diseases. Curr Opin Genet Dev (2009) 6.85

Prevalence of conventional risk factors in patients with coronary heart disease. JAMA (2003) 6.84

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA (2011) 6.39

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol (2011) 6.35

Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA (2004) 6.28

9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response. Nature (2011) 6.25

Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med (2009) 6.18

European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10

Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA (2005) 5.93

Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med (2003) 5.89

Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med (2014) 5.88

Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA (2006) 5.78

A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol (2003) 5.51

ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation (2009) 5.49

Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg (2012) 5.49

Bivalirudin for patients with acute coronary syndromes. N Engl J Med (2006) 5.49

Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet (2003) 5.34

The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet (2004) 5.31

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res (2009) 5.20

Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. N Engl J Med (2009) 5.19

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis (2007) 5.15

Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA (2004) 5.11

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation (2011) 5.09

Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med (2006) 5.07

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet (2002) 5.04

Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol (2007) 4.99

Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation (2011) 4.95

Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81

Microdroplet-based PCR enrichment for large-scale targeted sequencing. Nat Biotechnol (2009) 4.80

Reliable noninvasive coronary angiography with fast submillimeter multislice spiral computed tomography. Circulation (2002) 4.78

Can mobile health technologies transform health care? JAMA (2013) 4.75

Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med (2003) 4.72

Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J (2003) 4.70

High-resolution spiral computed tomography coronary angiography in patients referred for diagnostic conventional coronary angiography. Circulation (2005) 4.68

ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography). Circulation (2007) 4.66

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. Ann Intern Med (2015) 4.62

A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet (2005) 4.45

N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation (2003) 4.31

Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med (2007) 4.30

Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med (2015) 4.27

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA (2005) 4.23

Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med (2013) 4.16

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol (2012) 4.13

Pathway analysis of seven common diseases assessed by genome-wide association. Genomics (2008) 4.11

Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA (2011) 4.09

A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts. N Engl J Med (2004) 4.07

Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med (2006) 4.07

Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet (2010) 3.97

Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization And Urgent Intervention Triage Strategy (ACUITY) substudy. Circulation (2010) 3.95

Protected carotid stenting in high-surgical-risk patients: the ARCHeR results. J Vasc Surg (2006) 3.77

Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res (2011) 3.72

Conversion of cardiovascular conference abstracts to publications. Circulation (2012) 3.71

Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med (2008) 3.68

Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent. J Exp Med (2006) 3.65

Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA (2008) 3.64

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet (2004) 3.57

Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA (2005) 3.54

Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA (2007) 3.48

Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the task force on infective endocarditis of the European society of cardiology. Eur Heart J (2004) 3.45

Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation (2006) 3.45

Assessing the association of appropriateness of coronary revascularization and clinical outcomes for patients with stable coronary artery disease. J Am Coll Cardiol (2012) 3.45